Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 17, 2020
Daily News
June 17, 2020
- Japan Biotech Group Submits Request to Health Minister on Coronavirus-Tied Development
June 17, 2020
- 0.1% of Tokyo Residents Test Positive for Coronavirus Antibodies: MHLW
June 17, 2020
- Label Revisions Ordered for Avastin, Memary
June 17, 2020
- Canada OKs Sunovion’s Apomorphine Sublingual Film for Parkinson’s
June 17, 2020
- 10 Foreign Makers in Japan Grow Above Market with 5.5% Sales Rise in 2019
June 17, 2020
- Distributors See 800 Item Shortages as Good Guesstimate as They Share Off-Year Survey Concerns with Chuikyo Wholesaler Rep
June 17, 2020
- Astellas Relaxes Commuting Rate Limit to 50% at HQ as COVID-19 Situation Improves
June 17, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…